有序開展防疫物資出口。中國在滿足國內(nèi)疫情防控需要的基礎(chǔ)上，想方設(shè)法為各國采購防疫物資提供力所能及的支持和便利，打通需求對接、貨源組織、物流運(yùn)輸、出口通關(guān)等方面堵點(diǎn)，暢通出口環(huán)節(jié)，有序開展防疫物資出口。采取有力措施嚴(yán)控質(zhì)量、規(guī)范秩序，發(fā)布防疫用品國外市場準(zhǔn)入信息指南，加強(qiáng)防疫物資市場和出口質(zhì)量監(jiān)管，保質(zhì)保量向國際社會提供抗擊疫情急需的防疫物資。3月1日至5月31日，中國向200個國家和地區(qū)出口防疫物資，其中，口罩706億只，防護(hù)服3.4億套，護(hù)目鏡1.15億個，呼吸機(jī)9.67萬臺，檢測試劑盒2.25億人份，紅外線測溫儀4029萬臺，出口規(guī)模呈明顯增長態(tài)勢，有力支持了相關(guān)國家疫情防控。1月至4月，中歐班列開行數(shù)量和發(fā)送貨物量同比分別增長24%和27%，累計運(yùn)送抗疫物資66萬件，為維持國際產(chǎn)業(yè)鏈和供應(yīng)鏈暢通、保障抗疫物資運(yùn)輸發(fā)揮了重要作用。

China has made arrangements for orderly exports of protective materials.While ensuring domestic needs, China has tried every possible means to provide support to all countries in purchasing protective materials. It has smoothed the channels for supply-demand docking, organized logistics, transport, and the supply of goods, and accelerated export customs clearance. It has taken effective measures to control product quality, regulate export procedures, issue guidelines on foreign market access, and strengthen market and export quality supervision, so as to provide other countries with goods of the highest quality. From March 1 to May 31, China exported protective materials to 200 countries and regions, among which there were more than 70.6 billion masks, 340 million protective suits, 115 million pairs of goggles, 96,700 ventilators, 225 million test kits, and 40.29 million infrared thermometers.

China’s growing exports provide strong support for the prevention and control efforts of affected countries. From January to April, the number of China-Europe freight trains and the volume of goods delivered increased by 24 percent and 27 percent compared with the same period last year, and a total of 660,000 packages were transported. This has played an important role in maintaining a smooth flow of international industrial and supply chains, and in ensuring the delivery of protective supplies to relevant countries.

　　開展國際科研交流合作。加強(qiáng)同世界衛(wèi)生組織溝通交流，同有關(guān)國家在溯源、藥物、疫苗、檢測等方面開展科研交流與合作，共享科研數(shù)據(jù)信息，共同研究防控和救治策略?？萍疾?、國家衛(wèi)生健康委、中國科協(xié)、中華醫(yī)學(xué)會聯(lián)合搭建“新型冠狀病毒肺炎科研成果學(xué)術(shù)交流平臺”，供全球科研人員發(fā)布成果、參與研討，截至5月31日，共上線104種期刊、970篇論文和報告。國家中醫(yī)藥管理局聯(lián)合上合組織睦鄰友好合作委員會召開“中國中西醫(yī)結(jié)合專家組同上海合作組織國家醫(yī)院新冠肺炎視頻診斷會議”，指導(dǎo)世界中醫(yī)藥學(xué)會聯(lián)合會和世界針灸學(xué)會聯(lián)合會開展“中醫(yī)藥抗疫全球直播”“國際抗疫專家大講堂”等活動。中國科學(xué)院發(fā)布“2019新型冠狀病毒資源庫”，建成“新型冠狀病毒國家科技資源服務(wù)系統(tǒng)”“新型冠狀病毒肺炎科研文獻(xiàn)共享平臺”，截至5月31日，3個平臺為全球超過37萬用戶提供近4800萬次下載、瀏覽和檢索服務(wù)。建立國際合作專家?guī)欤嘘P(guān)國家開展疫苗研發(fā)、藥品研發(fā)等合作。充分發(fā)揮“一帶一路”國際科學(xué)組織聯(lián)盟作用，推動成員之間就新冠病毒研究和新冠肺炎治療開展科技合作。中國醫(yī)療機(jī)構(gòu)、疾控機(jī)構(gòu)和科學(xué)家在《柳葉刀》《科學(xué)》《自然》《新英格蘭醫(yī)學(xué)雜志》等國際知名學(xué)術(shù)期刊上發(fā)表數(shù)十篇高水平論文，及時發(fā)布新冠肺炎首批患者臨床特征描述、人際傳播風(fēng)險、方艙醫(yī)院經(jīng)驗、藥物研發(fā)進(jìn)展、疫苗動物實(shí)驗結(jié)果等研究成果。同有關(guān)國家、世界衛(wèi)生組織以及流行病防范創(chuàng)新聯(lián)盟（CEPI）、全球疫苗免疫聯(lián)盟（GAVI）等開展科研合作，加快推進(jìn)疫苗研發(fā)和藥物臨床試驗。

China has carried out international exchanges and cooperation on scientific research.China has strengthened communication and exchanges with the WHO, conducted exchanges and cooperation with other countries on research in virus traceability, medicines, vaccines, and testing, shared scientific research data and information, and jointly studied prevention, control and treatment strategies. The Ministry of Science and Technology, the NHC, the China Association for Science and Technology, and the Chinese Medical Association have jointly put in place a Covid-19 Academic Research Communication Platform for worldwide researchers to release results and participate in discussion. By May 31, a total of 104 journals and 970 papers and reports had been posted. The National Administration of Traditional Chinese Medicine and the SCO Committee on Good-Neighborliness, Friendship and Cooperation held a video conference on the diagnosis and treatment of Covid-19 between a group of Chinese experts on integrating traditional Chinese medicine and Western medicine, and hospitals from SCO countries. It also guided the World Federation of Chinese Medicine Societies and the World Federation of Acupuncture-Moxibustion Societies in organizing such events as Expert Dialogue on Covid-19 Prevention and Control with Traditional Chinese Medicine and International Lectures on Covid-19.

The Chinese Academy of Sciences has released the 2019 Novel Coronavirus Resource database, and built the Novel Coronavirus National Science and Technology Resource Service System and the Covid-19 Pneumonia Scientific Literature Sharing Platform. As of May 31, the three platforms had provided nearly 48 million download, browsing and retrieval services to more than 370,000 users worldwide. China has established an international pool of experts and has cooperated with other countries in vaccine and medicine research and development. It has encouraged the Alliance of International Science Organizations in the framework of the Belt and Road Initiative to promote cooperation among its members in Covid-19 treatment and research. Chinese scientists, medical institutions, and disease control centers have published dozens of well-researched papers in some of the world’s leading academic journals such as The Lancet, Science, Nature and The New England Journal of Medicine, releasing timely results of tests on the first patients, including the clinical characteristics of the virus, the risk of human-to-human transmission, China’s experience of temporary treatment centers, medicine research and development, and experimental results of vaccines on animals. To accelerate the development of vaccines and the clinical trials of medicines, China has also carried out cooperation in scientific research with other countries, and with such organizations as the WHO, the Coalition for Epidemic Preparedness and Innovation and the Global Alliance for Vaccines and Immunisation.